Tirzepatide is a groundbreaking therapeutic agent for individuals facing type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) https://gretapnwf231625.onzeblog.com/40745597/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist